Nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Several experts called the U.S. airdrops performative and said they would do little to alleviate the famine in Gaza. Biden continued to support Israel during the course of the war despite significant domestic opposition to American involvement in it and subsequent widespread protests. A March 2024 Gallup poll found that a strong majority of Americans disapproved of Israeli conduct during the war. Beginning in April 2024, widespread Gaza war protests emerged on university campuses, denouncing Biden. On May 31, 2024, Biden announced his support for an Israeli ceasefire proposal, saying that Hamas was "no longer capable" of another large-scale attack. The proposal, which was intended to establish a permanent ceasefire, bring about the release of all hostages, and lead to the reconstruction of the Gaza Strip, was supported by Hamas officials after mediation by Egypt and Qatar. The Netanyahu administration responded that Israel's goals regarding "the destruction of Hamas military and governing capabilities" had not changed and that conditions would need to be met before it would agree to a ceasefire. In the first year of the war, it was estimated that the Biden administration had sent Israel at least $17.9 billion in military aid, a record. In about the same period, it sent Palestinians $1.2 billion in humanitarian aid. Biden was reported by journalist Bob Woodward to have clashed throughout the war with Netanyahu over his war strategy and lack of a postwar plan for Gaza.
Dzhambulat Khatokhov (1999–2020), a Russian boy who weighed 75 lb (34 kg; 5.4 st) at 2 years old and 397 lb (180 kg; 28.4 st) at 13 years old. He was named the world's heaviest child in 2003 by Guinness World Records. Jessica Leonard (born c. 1997–1998), also known as Jessica Gaude, an American girl who reportedly weighed 490 lb (220 kg; 35 st) at 7 years old, and 420 lb (190 kg; 30 st) at 8 years old. Arya Permana (born 2006), an Indonesian boy who weighed 423 lb (192 kg; 30.2 st) at 11 years old. Eugenia Martínez Vallejo, a Spanish girl who lived in the 17th century, gained notoriety for her large size and weight and notably became a court jester for Charles II of Spain. Her obesity is today thought to have been caused by Prader-Willi syndrome.
In 1928, under Joseph Peter Grace's leadership, an agreement between Grace and Pan American formed Pan American-Grace Airways (or Panagra), a United States international carrier flying down the west coast of South America. Panagra ultimately evolved into a jet carrier flying from Miami and New York to South America before merging with Braniff Airways in 1967, becoming Braniff's South American network. These routes were sold to Eastern Air Lines in 1982 and then to American Airlines in 1990. In 1929, the vice president at that time, D. Stewart Inglehart, became president, and Joseph Peter Grace was elected chairman of the board of the company.In 1945, the founder's grandson and Joseph Peter Grace's son, J. Peter Grace, became president. Under his leadership, the company owned the country's largest oil-drilling fleet as of 1990-1993, managed its subsidiary Grace Cocoa, which was one of the world's leading suppliers of cocoa bean and chocolate ingredients as of 1992, as well as sugar plantations in Peru, cotton mills in Chile, silver, clay, phosphate, and tin mines. Through its Davison Chemical Division, the company had processed various nuclear materials under a contract from the United States Atomic Energy Commission (AEC). New companies such as Grace Petroleum, Grace Drilling, and Grace Healthcare were created under the umbrella of the Grace Corporation. Grace owned a food group that operated 900 chain restaurant locations, and a retail division with chains for sporting goods, home improvement, jewelry, aftermarket automotive parts and leather goods.
The secession of the Liberal Republican Union in March 1926, and the beginning of the Ditadura Nacional at the end of May of the same year, marked the end of the Nationalist Republican Party. In the early 1930s many former members of the PRN joined the National Union, ruling party of the Estado Novo.
X-rays of the hands and feet are generally performed when many joints are affected. In RA, there may be no changes in the early stages of the disease, or the X-ray may show osteopenia near the joint, soft tissue swelling, and a smaller than normal joint space. As the disease advances, there may be bony erosions and subluxation. Other medical imaging techniques such as magnetic resonance imaging (MRI) and ultrasound are also used in RA. Technical advances in ultrasonography, like high-frequency transducers (10 MHz or higher), have improved the spatial resolution of ultrasound images, depicting 20% more erosions than conventional radiography. Color Doppler and power Doppler ultrasound are useful in assessing the degree of synovial inflammation as they can show vascular signals of active synovitis. This is important since in the early stages of RA, the synovium is primarily affected, and synovitis seems to be the best predictive marker of future joint damage.
Sources: en.wikipedia.org
== History == Frank P. Cotter developed a "simple self sealing check valve, adapted to be connected in the pipe connections without requiring special fittings and which may be readily opened for inspection or repair" 1907 (U.S. patent 865,631). Nikola Tesla invented a deceptively simple one-way valve for fluids in 1916, called a Tesla valve. It was patented in 1920 (U.S. patent 1,329,559).
== Corneal keratocytes == Keratocytes are flattened cells found dispersed within the corneal stroma. The primary role of this sparse population of cells is thought to be in maintaining the extracellular matrix of collagen lamellae that surround them. However, keratocytes also play a defensive role during pathogenic invasion. They can be influenced by IL-1α (secreted by corneal epithelial cells) and tumor necrosis factor (TNF)-α to produce both IL-6 and defensins. Of these, the former is found to combine synergistically with other interleukins to increase co-stimulation of other immune aspects as well as increase antibody secretion. The latter, defensins, have a wide range of antimicrobial affects against bacteria, fungi, and viruses, as well as effects in accelerating healing of damaged epithelial cells. It has also been found that the presence of secreted defensins secreted by corneal keratocytes is correlated with cases of corneal transplant rejection, suggesting that these peptides may have a role in tissue rejection. Furthermore, keratocytes have also been found to secrete IL-8, which attracts neutrophils, in infections involving the herpes simplex virus.
LSD, a classical psychedelic, is deemed physiologically safe at standard doses (50–200 μg), and its primary risks lie in psychological effects rather than physiological harm. A 2010 study by David Nutt ranked LSD as significantly less harmful than alcohol, placing it near the bottom of a list assessing the harm of 20 drugs.
As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required. The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations. It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination.
Sources: en.wikipedia.org
Manufacturing sites were opened in 2011 in the Czech Republic for the industrial, pharmaceutical, chemical, and scientific markets while manufacturing sites for the semiconductor market were opened in South Korea. Most of Edwards' UK manufacturing capacity was moved, with abatement systems remaining in Clevedon, completing plans proposed under BOC in 2005. Edwards was awarded its seventh Queen's Award in 2012, and acquired USA-based Gamma Vacuum in 2013, maintaining the brand until this day. Gamma Vacuum specialises in ion and titanium sublimation pumps, with customers mainly in the scientific industry.
N-Desalkylflurazepam (also known as norflurazepam) is a benzodiazepine analog and an active metabolite of several other benzodiazepine drugs including flurazepam, flutoprazepam, fludiazepam, midazolam, flutazolam, quazepam, and ethyl loflazepate. It is long-acting, prone to accumulation, and binds unselectively to the various benzodiazepine receptor subtypes. It has been sold as a designer drug from 2016 onward.
=== Degradation === Once an insulin molecule has docked onto the receptor and effected its action, it may be released back into the extracellular environment, or it may be degraded by the cell. The two primary sites for insulin clearance are the liver and the kidney. The liver clears most insulin during first-pass transit, whereas the kidney clears most of the insulin in systemic circulation. Degradation normally involves endocytosis of the insulin-receptor complex, then the action of insulin-degrading enzyme on the B-chain, followed by the disulfide bond being broken by enzymes from the protein disulfide isomerase family. An insulin molecule produced endogenously by the beta cells is estimated to be degraded within about one hour after its initial release into circulation (insulin half-life ~ 4–6 minutes).
== Uses == Niosomes are used as biodegradable and non-immunogenic drug delivery compounds, as they have a low toxicity risk in biological systems. They can also be used to entrap hydrophilic pharmaceuticals within aqueous compartments or lipophilic drugs into vesicular bilayer membranes. Niosomes shield drug molecules from the biological environment, which can be utilized to improve the therapeutic performance of various drug molecules. Additionally, they can be used in a sustained drug delivery system to more directly affect target cells and delay clearance from circulation. Niosomes are used in a variety of applications, including gene delivery, drug targeting, antineoplastic treatment, delivery of peptide drugs, carriers for hemoglobin, transdermal drug delivery systems, and cosmetics. They are also being studied for their potential use as a treatment for different forms of leishmaniasis In one 2022 in vitro study, tamoxifen-loaded niosomes exhibited pH-dependent release and induced apoptosis and cell-cycle arrest in two breast cancer cell lines .
== History == Beginning in 2007, the British Engineering and Physical Sciences Research Council has funded development of ribosome-like molecular assemblers. Clearly, molecular assemblers are possible in this limited sense. A technology roadmap project, led by the Battelle Memorial Institute and hosted by several U.S. National Laboratories has explored a range of atomically precise fabrication technologies, including both early-generation and longer-term prospects for programmable molecular assembly; the report was released in December, 2007. In 2008, the Engineering and Physical Sciences Research Council provided funding of £1.5 million over six years (£1,942,235.57, $2,693,808.00 in 2021) for research working towards mechanized mechanosynthesis, in partnership with the Institute for Molecular Manufacturing, amongst others. Likewise, the term "molecular assembler" has been used in science fiction and popular culture to refer to a wide range of fantastic atom-manipulating nanomachines. Much of the controversy regarding "molecular assemblers" results from the confusion in the use of the name for both technical concepts and popular fantasies. In 1992, Drexler introduced the related but better-understood term "molecular manufacturing", which he defined as the programmed "chemical synthesis of complex structures by mechanically positioning reactive molecules, not by manipulating individual atoms". This article mostly discusses "molecular assemblers" in the popular sense.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.